- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
- PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
- PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
- PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
- PaxMedica Announces 1-for-17 Reverse Stock Split
- PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
More ▼
Key statistics
On Friday, PaxMedica Inc (PXMD:PKC) closed at 0.2401, 19.45% above the 52 week low of 0.201 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.275 |
---|---|
High | 0.275 |
Low | 0.222 |
Bid | -- |
Offer | -- |
Previous close | 0.2438 |
Average volume | 121.88k |
---|---|
Shares outstanding | 7.78m |
Free float | 6.80m |
P/E (TTM) | -- |
Market cap | 1.87m USD |
EPS (TTM) | -11.19 USD |
Data delayed at least 15 minutes, as of May 17 2024 20:59 BST.
More ▼